Given that PTEN gene is often wild-type in human breast cancers (Stemke-Hale et al., 2008; Chalhoub and Baker, 2009), further experiments may reveal that p110δ-selective inhibitors alone or combined with inhibitors of other components of PI3K pathway could be beneficial in this cancer type. Here, PIK3CA is linked to breast carcinoma.